Taiwan · Delayed Price · Currency is TWD Concord Medical Statistics
Total Valuation
Concord Medical has a market cap or net worth of TWD 910.00 million. The enterprise value is 989.42 million.
| Market Cap | 910.00M |
| Enterprise Value | 989.42M |
Important Dates
The last earnings date was Friday, March 13, 2026.
| Earnings Date | Mar 13, 2026 |
| Ex-Dividend Date | Apr 10, 2026 |
Share Statistics
Concord Medical has 33.33 million shares outstanding. The number of shares has increased by 0.06% in one year.
| Current Share Class | 33.33M |
| Shares Outstanding | 33.33M |
| Shares Change (YoY) | +0.06% |
| Shares Change (QoQ) | -0.23% |
| Owned by Insiders (%) | 5.70% |
| Owned by Institutions (%) | n/a |
| Float | 10.33M |
Valuation Ratios
The trailing PE ratio is 13.58.
| PE Ratio | 13.58 |
| Forward PE | n/a |
| PS Ratio | 0.94 |
| PB Ratio | 1.21 |
| P/TBV Ratio | 1.29 |
| P/FCF Ratio | 7.37 |
| P/OCF Ratio | 5.79 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.27, with an EV/FCF ratio of 8.02.
| EV / Earnings | 14.69 |
| EV / Sales | 1.03 |
| EV / EBITDA | 6.27 |
| EV / EBIT | 13.60 |
| EV / FCF | 8.02 |
Financial Position
The company has a current ratio of 1.78, with a Debt / Equity ratio of 0.24.
| Current Ratio | 1.78 |
| Quick Ratio | 1.27 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | 1.13 |
| Debt / FCF | 1.45 |
| Interest Coverage | 18.69 |
Financial Efficiency
Return on equity (ROE) is 9.36% and return on invested capital (ROIC) is 7.39%.
| Return on Equity (ROE) | 9.36% |
| Return on Assets (ROA) | 3.82% |
| Return on Invested Capital (ROIC) | 7.39% |
| Return on Capital Employed (ROCE) | 8.24% |
| Weighted Average Cost of Capital (WACC) | 5.42% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.81 |
| Inventory Turnover | 124.45 |
Taxes
In the past 12 months, Concord Medical has paid 14.90 million in taxes.
| Income Tax | 14.90M |
| Effective Tax Rate | 17.99% |
Stock Price Statistics
The stock price has increased by +4.20% in the last 52 weeks. The beta is 0.34, so Concord Medical's price volatility has been lower than the market average.
| Beta (5Y) | 0.34 |
| 52-Week Price Change | +4.20% |
| 50-Day Moving Average | 26.44 |
| 200-Day Moving Average | 26.27 |
| Relative Strength Index (RSI) | 57.99 |
| Average Volume (20 Days) | 13,420 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Concord Medical had revenue of TWD 964.35 million and earned 67.36 million in profits. Earnings per share was 2.01.
| Revenue | 964.35M |
| Gross Profit | 133.96M |
| Operating Income | 72.78M |
| Pretax Income | 82.83M |
| Net Income | 67.36M |
| EBITDA | 157.74M |
| EBIT | 72.78M |
| Earnings Per Share (EPS) | 2.01 |
Balance Sheet
The company has 125.18 million in cash and 178.42 million in debt, with a net cash position of -53.24 million or -1.60 per share.
| Cash & Cash Equivalents | 125.18M |
| Total Debt | 178.42M |
| Net Cash | -53.24M |
| Net Cash Per Share | -1.60 |
| Equity (Book Value) | 754.13M |
| Book Value Per Share | 21.82 |
| Working Capital | 264.51M |
Cash Flow
In the last 12 months, operating cash flow was 157.24 million and capital expenditures -33.82 million, giving a free cash flow of 123.42 million.
| Operating Cash Flow | 157.24M |
| Capital Expenditures | -33.82M |
| Depreciation & Amortization | 84.97M |
| Net Borrowing | -38.50M |
| Free Cash Flow | 123.42M |
| FCF Per Share | 3.70 |
Margins
Gross margin is 13.89%, with operating and profit margins of 7.55% and 6.99%.
| Gross Margin | 13.89% |
| Operating Margin | 7.55% |
| Pretax Margin | 8.59% |
| Profit Margin | 6.99% |
| EBITDA Margin | 16.36% |
| EBIT Margin | 7.55% |
| FCF Margin | 12.80% |
Dividends & Yields
This stock pays an annual dividend of 1.10, which amounts to a dividend yield of 4.03%.
| Dividend Per Share | 1.10 |
| Dividend Yield | 4.03% |
| Dividend Growth (YoY) | 36.36% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 54.43% |
| Buyback Yield | -0.06% |
| Shareholder Yield | 3.97% |
| Earnings Yield | 7.40% |
| FCF Yield | 13.56% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |